Eli Lilly & Co. said Thursday it plans to withdraw its cancer drug Lartruvo from the market after a study showed that it failed to prolong overall survival in a clinical trial.
The company will establish an access program to allow some patients with soft-tissue sarcoma—a cancer that develops in connective tissue including muscle—to continue taking the drug with limited interruption after it’s withdrawn from the market. Lilly didn’t provide a specific timeline and said it’s working with health regulators on its plans.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MarketWatch - 🏆 3. / 97 Read more »